FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/14/2022
Back to search
Official data from USPTO
VETTER-JECT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
VETTER-JECT
ST13
US500000079250207Class
5, 10, 39, 42
Filing
79250207
Registration
6791709
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
11/14/2022
Trademark type
Word
Nice classes
5, 10, 39, 42
Filing date
09/24/2018
Registration date
07/19/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/19/2022
Last transaction
07/19/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
13
Owner location
DE
Examiner
AGREDA, SAMANTHA
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Vetter Pharma-Fertigung GmbH & Co. KG
Representatives
M. Scott Alprin Alprin Law Offices, P.C.
Technical classification
Nice Classes
Class 5Class 10Class 39Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and medicines for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of sterile aseptic solutionsnamely in the form of tabletspillscapsulesdropsmedical juice and medical syrupall for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; injectable pharmaceuticals in the nature of antibody solutionsbiologicalspeptidespolypeptidesproteinsenzymesnucleic acidscoagulation factorsinterferonsphosphonates and bisphosphonatesgrowth factorshormoneshormoneantagonistsinsulinheparinslow molecular heparins and sulfur hexafluorideall for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; eyedropscontact lens solutions; medicated compresses; medical plastersmaterials for dressings in the nature of bandageswadding and gauze; filled medical injection devicesin particular syringes and instruments for injectionsinjectorsauto-injectors and single-chamber and dual-chamber disposable syringesall sold filled with pharmaceutical preparations for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunction inflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia
Class 10
Empty medical injection devicesin particular syringes and instruments for injectionsinjectorsauto-injectors and single-chamber and dual-chamber disposable syringesall sold empty; medicine containers for administering medicinesof glass and/or plastic in the nature of medical syringesinjectorsauto-injectorsdisposable syringes and disposable cannulae; syringe holders being containers specially adapted for holding medical syringes; medical syringesdisposable syringesdisposable cannulae sold either individually or in combinationall for medical purposes
Class 39
Bottling servicesbottling of liquid and solid substancesin particular of pharmaceuticalsmedicines and solutions
Class 42
Development of syringes and instruments for injectionsinjectors and packaging for the aforesaid goods; laboratory tests in the nature of scientific testing in the fields of chemicalphysics and process engineering; product development and conducting of scientific tests in the fields of pharmacological and microbiological processes
Publications
History of USPTO decisions and trademark events.
51 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/22/2022
FIMP
FINAL DISPOSITION PROCESSED
10/22/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/19/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/19/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
07/19/2022
GPNX
NOTIFICATION PROCESSED BY IB
05/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/03/2022
PUBO
PUBLISHED FOR OPPOSITION
05/03/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/13/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/13/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/13/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/27/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/26/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/25/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/25/2022
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
09/27/2021
GNCF
CONTINUATION OF FINAL REFUSAL E-MAILED
09/27/2021
CNCF
ACTION CONTINUING A FINAL - COMPLETED
09/27/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/28/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/16/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/28/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/28/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
10/02/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/12/2020
GNSL
LETTER OF SUSPENSION E-MAILED
03/12/2020
CNSL
SUSPENSION LETTER WRITTEN
03/12/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/10/2020
ALIE
ASSIGNED TO LIE
03/10/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/05/2020
GNSL
LETTER OF SUSPENSION E-MAILED
03/05/2020
CNSL
SUSPENSION LETTER WRITTEN
03/05/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/04/2020
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
12/06/2019
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
11/29/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/05/2019
GNFR
FINAL REFUSAL E-MAILED
09/05/2019
CNFR
FINAL REFUSAL WRITTEN
09/05/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/13/2019
RFNT
REFUSAL PROCESSED BY IB
03/02/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/13/2019
RFRR
REFUSAL PROCESSED BY MPU
02/12/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/05/2019
CNRT
NON-FINAL ACTION WRITTEN
02/04/2019
MAFR
APPLICATION FILING RECEIPT MAILED
02/01/2019
DOCK
ASSIGNED TO EXAMINER
01/28/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/28/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/24/2019
Continuous trademark protection
Get notified about every new filing that threatens VETTER-JECT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.